A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

Ola Lindén, Jan Kurkus, Michael Garkavij, Eva Cavallin-Ståhl, Michael Ljungberg, Rune Nilsson, Tomas G Ohlsson, Bengt Sandberg, Sven-Erik Strand, Jan Tennvall

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)457-466
JournalCancer Biotherapy & Radiopharmaceuticals
Issue number4
Publication statusPublished - 2005

Subject classification (UKÄ)

  • Cancer and Oncology

Cite this